XENIKOS

Xenikos develops innovative new immunotherapies, based on conjugated antibodies (anti-CD3 / anti-CD7), designed to improve patient health and quality of life. This powerful therapeutic approach helps to reset the immune system in patients with a severe immune disease or post-transplantation rejection. Xenikos’ flagship product, T-Guard™, is being prepared to enter Phase 3 testing for the second-line treatment of steroid-resistant acute graft-versus-host-disease in patients following hematopoietic stem cell transplantation.

www.xenikos.com